Get access

The Risk of Newly Diagnosed Asthma in Migraineurs With or Without Previous Triptan Prescriptions

Authors

  • Claudia Becker PhD, MSc,

    1. From the Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland (C. Becker and C.R. Meier); AstraZeneca Research & Development, Södertälje, Sweden (G.P. Brobert and P.M. Almqvist); AstraZeneca Research & Development, Mölndal, Sweden (S. Johansson); Section of Preventive Cardiology, Göteborg University, Göteborg, Sweden (S. Johansson); Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA, USA (S.S. Jick and C.R. Meier)
    Search for more papers by this author
  • Gunnar P. Brobert PhD,

    1. From the Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland (C. Becker and C.R. Meier); AstraZeneca Research & Development, Södertälje, Sweden (G.P. Brobert and P.M. Almqvist); AstraZeneca Research & Development, Mölndal, Sweden (S. Johansson); Section of Preventive Cardiology, Göteborg University, Göteborg, Sweden (S. Johansson); Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA, USA (S.S. Jick and C.R. Meier)
    Search for more papers by this author
  • Per M. Almqvist MD, PhD,

    1. From the Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland (C. Becker and C.R. Meier); AstraZeneca Research & Development, Södertälje, Sweden (G.P. Brobert and P.M. Almqvist); AstraZeneca Research & Development, Mölndal, Sweden (S. Johansson); Section of Preventive Cardiology, Göteborg University, Göteborg, Sweden (S. Johansson); Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA, USA (S.S. Jick and C.R. Meier)
    Search for more papers by this author
  • Saga Johansson MD, PhD,

    1. From the Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland (C. Becker and C.R. Meier); AstraZeneca Research & Development, Södertälje, Sweden (G.P. Brobert and P.M. Almqvist); AstraZeneca Research & Development, Mölndal, Sweden (S. Johansson); Section of Preventive Cardiology, Göteborg University, Göteborg, Sweden (S. Johansson); Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA, USA (S.S. Jick and C.R. Meier)
    Search for more papers by this author
  • Susan S. Jick DSc,

    1. From the Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland (C. Becker and C.R. Meier); AstraZeneca Research & Development, Södertälje, Sweden (G.P. Brobert and P.M. Almqvist); AstraZeneca Research & Development, Mölndal, Sweden (S. Johansson); Section of Preventive Cardiology, Göteborg University, Göteborg, Sweden (S. Johansson); Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA, USA (S.S. Jick and C.R. Meier)
    Search for more papers by this author
  • Christoph R. Meier PhD, MSc

    1. From the Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland (C. Becker and C.R. Meier); AstraZeneca Research & Development, Södertälje, Sweden (G.P. Brobert and P.M. Almqvist); AstraZeneca Research & Development, Mölndal, Sweden (S. Johansson); Section of Preventive Cardiology, Göteborg University, Göteborg, Sweden (S. Johansson); Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA, USA (S.S. Jick and C.R. Meier)
    Search for more papers by this author

  • Conflict of Interest: This study was funded with an unconditional grant by AstraZeneca R&D, Mölndal, Sweden.

C.R. Meier, Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Hebelstrasse 2, CH-4031 Basel, Switzerland.

Abstract

Background.— Previous observational studies reported an increased prevalence of asthma in migraine patients. Whether triptans affect the asthma risk has not yet been explored in an epidemiological study.

Objective.— To estimate the risk of newly diagnosed asthma in patients with a general practitioner-diagnosed migraine in the UK between 1994 and 2001.

Methods.— A population-based follow-up study and a nested case-control analysis were conducted using the General Practice Research Database.

Results.— The study encompassed 51,688 migraineurs and the same number of matched controls. In the follow-up analysis, the relative risk of developing asthma in migraineurs compared with non-migraineurs was 1.3 (95% confidence interval [CI] 1.1-1.4). In the nested case-control analysis, the adjusted odds ratio for asthma in migraineurs overall was 1.17 (95% CI 1.01-1.35), and for those with a recent triptan prescription 1.12 (95% CI 0.65-1.94).

Conclusion.— The risk of developing asthma was not materially altered for patients with a general practitioner-recorded migraine diagnosis, regardless of triptan use.

Get access to the full text of this article

Ancillary